Lucentis (ranibizumab) has been approved by the Therapeutics Goods Administration (TGA) for the treatment of retinopathy of prematurity (ROP), a rare and potentially blinding

Hear from the godfather of intense pulsed light (IPL) technology, Dr Rolando Toyos, at the Australian Dry Eye Summit, presented by Lumenis on 13

Although seemingly counterintuitive, more frequent screening of at-risk glaucoma suspects by optometrists in clinical practice can reduce clinic load and lower costs up to

‘Front loading’ visual field tests is a feasible approach to better understand a patient’s condition and disease progression, with minimal compromise to clinical workflow,